17.54
-5.4(-23.54%)
Currency In USD
Address
945 Concord Street
Framingham, NV
United States of America
Phone
N/A
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
July 23, 2019
| Name | Title | Pay | Year Born |
| Mr. James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary | 399,800 | 1965 |
| Mr. Jeffrey F. Eisenberg Esq. | President & Director | 495,631 | 1966 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.